The on-target effects of gliflozins (SGLT2 inhibition), resulting in reduced glucose transport, have already led to investigation of their effects on cancers such as lung adenocarcinoma, colon adenocarcinoma, hepatocellular carcinoma and adult T-cell leukaemia, where tumour growth was impeded [[12], [13], [14], [15]]. This evidence concerns the gene SLC5A2 and cancer.